VCID Biomarker's Coordinating Center

VCID生物标志物协调中心

• 批准号: 9516183
• 负责人: Steven M Greenberg
• 金额: $ 47.23万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-30 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9516183
• 关键词: Age; Age-associated memory impairment; Alzheimer' s Disease; Area; Biological; Biological Markers; Biology; Blood Vessels; Body Fluids; Brain; Cerebral small vessel disease; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Complex; Consensus; Country; Data; Data Collection; Data Storage and Retrieval; Decision Making; Dementia; Disease; Future; General Hospitals; Goals; Impaired cognition; Incidence; Income; Individual; Intervention; Intervention Trial; Lead; Leadership; Liquid substance; Magnetic Resonance Imaging; Massachusetts; Medical; Methods; Microvascular Dysfunction; National Institute of Neurological Disorders and Stroke; Office of Administrative Management; Positioning Attribute; Prevention; Principal Investigator; Procedures; Public Health; Recommendation; Regulation; Research; Research Infrastructure; Research Personnel; Research Priority; Sampling; Scanning; Site; Stroke; Structure; Technology; Testing; Training; United States National Institutes of Health; Validation; Variant; base; biomarker validation; cardiovascular health; data management; design; epidemiology study; experience; innovation; international center; multimodality; outreach; response; skills; validation studies; vascular cognitive impairment and dementia

PROJECT SUMMARY/ABSTRACT The vascular contribution to cognitive impairment and dementia (VCID) driven by cerebral small vessel disease (SVD) is now recognized as a major public health threat. In response to the call from NINDS for a multisite consortium dedicated to identifying and validating biomarkers for SVD-related VCID, we propose to form the Massachusetts General Hospital (MGH) VCID Biomarkers Coordinating Center. The aims of the proposed coordinating center will be to provide outstanding scientific leadership and state-of-the-art administrative and data management infrastructure to the VCID biomarkers consortium. Specific strengths of the proposed MGH coordinating center include 1) the Principal Investigator's demonstrated high-level skill as a scientific pioneer in SVD biomarkers and an effective leader of complex multicenter projects and organizations, 2) an outstanding and experienced team of Administrative and Data Core directors, co-Investigators, and study staff capable of handling all aspects of a complex coordinating center, 3) innovative approaches to multimodal data handling and minimizing inter-scanner variations in MRI data, and 4) detailed organizational plans for efficient high-level decision-making by representative committees, creation of consortium standards for data collection and sharing, consortium-wide communication, and outreach to related external efforts. If selected, the proposed MGH coordinating center will be ideally positioned to lead the consortium to its goals of moving SVD biomarkers to the forefront of VCID clinical trials.

项目摘要/摘要 由脑小血管疾病驱动的认知障碍和痴呆（VCID）的血管贡献 （SVD）现在被认为是主要的公共卫生威胁。响应Ninds的呼吁 致力于识别和验证与SVD相关VCID的生物标志物的财团，我们建议形成 马萨诸塞州综合医院（MGH）VCID生物标志物协调中心。提议的目的 协调中心将提供出色的科学领导和最先进的行政和 VCID生物标志物联盟的数据管理基础架构。提议的MGH的特定优势 协调中心包括1）首席研究员的高级技能，作为科学先驱 SVD生物标志物和复杂多中心项目和组织的有效领导者，2） 以及经验丰富的行政和数据核心主管，共同研究人员以及能够的研究人员的团队 处理复杂协调中心的所有方面，3）多模式数据处理的创新方法 并最大程度地减少MRI数据中的扫描仪之间的变化，以及4）详细的组织计划，以进行高效高级 代表委员会的决策，创建联盟标准以收集数据和 共享，财团的沟通以及与相关外部努力的宣传。如果选择，则提议 MGH协调中心将是理想的位置 生物标志物位于VCID临床试验的最前沿。